Takeda Pharmaceutical Company Ltd

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

A Study of TAK-079 in People With Generalized Myasthenia Gravis

Phase 2

Completed

Conditions: Myasthenia Gravis

Interventions: Drug: TAK-079 Placebo
Drug: TAK-079

First Posted Date: 2019-11-12

Last Posted Date: 2023-06-02

Lead Sponsor: Takeda

Target Recruit Count: 36

Registration Number: NCT04159805

Locations: 🇺🇸
Neurology and Sleep Disorders Clinic, Columbia, Missouri, United States
🇮🇹
Fondazione Policlinico Universitario A Gemelli, Roma, Lazio, Italy
🇺🇸
The University of Arizona Medical Center, Tucson, Arizona, United States

and more 46 locations

A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

Phase 1

Terminated

Conditions: Melanoma
Neoplasms

Interventions: Drug: Modakafusp Alfa
Drug: Pembrolizumab

First Posted Date: 2019-11-08

Last Posted Date: 2024-12-27

Lead Sponsor: Takeda

Target Recruit Count: 45

Registration Number: NCT04157517

Locations: 🇺🇸
University of California San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸
Norris Cotton Cancer Center Lebanon, Lebanon, New Hampshire, United States
🇺🇸
Morristown Medical Center, Morristown, New Jersey, United States

and more 14 locations

A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of TAK-123 After Intravenous Infusion in Japanese Healthy Adult Male Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: TAK-123

First Posted Date: 2019-11-07

Last Posted Date: 2021-02-21

Lead Sponsor: Takeda

Target Recruit Count: 10

Registration Number: NCT04155567

Locations: 🇯🇵
Sekino Clinical Pharmacology Clinic, Toshima-ku, Tokyo, Japan

A Study of People With Multiple Myeloma (MM) in Portugal (CharisMMa-Portugal)

Completed

Conditions: Relapse and/or Refractory Multiple Myeloma

First Posted Date: 2019-10-23

Last Posted Date: 2023-10-23

Lead Sponsor: Takeda

Target Recruit Count: 62

Registration Number: NCT04135963

Locations: 🇵🇹
Instituto Portugues de Oncologia de Lisboa Francisco Gentil (IPO), Lisboa, Portugal
🇵🇹
Centro Hospitalar Lisboa Norte EPE - Hospital de Santa Maria, Lisboa, Portugal
🇵🇹
Centro Hospitalar Universitario de Sao Joao, EPE,, Porto, Portugal

and more 5 locations

TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Phase 3

Active, not recruiting

Conditions: Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Interventions: Drug: TAK-788
Drug: Pemetrexed
Drug: Cisplatin
Drug: Carboplatin

First Posted Date: 2019-10-16

Last Posted Date: 2024-11-28

Lead Sponsor: Takeda

Target Recruit Count: 354

Registration Number: NCT04129502

Locations: 🇮🇹
AORN Dei Colli- Ospedale Monaldi Napoli, Napoli, Campania, Italy
🇺🇦
Private Enterprise Private Manufacturing Company Acinus, Kropyvnytskyi, Ukraine
🇨🇳
Icahn School of Medicine at Mount Sinai, Beijing, China

and more 129 locations

A Study of Darvadstrocel in Adults With Crohn's Disease and Complex Perianal Fistula

Phase 4

Active, not recruiting

Conditions: Crohn's Disease
Complex Perianal Fistula

Interventions: Biological: Darvadstrocel

First Posted Date: 2019-10-08

Last Posted Date: 2024-02-20

Lead Sponsor: Takeda

Target Recruit Count: 50

Registration Number: NCT04118088

Locations: 🇩🇪
Charite - Campus Benjamin Franklin, Berlin, Germany
🇩🇪
Klinikum Dresden, University Hospital Dresden, Dresden, Sachsen, Germany
🇩🇪
Stadtisches Klinikum Luneburg, Luneburg, Schleswig-Holstein, Germany

and more 27 locations

Health-Related Quality of Life in Crohn's Disease Participants With Complex Perianal Fistula Before and After Treatment

Terminated

Conditions: Crohn Disease
Inflammatory Bowel Disease
Gastrointestinal Diseases
Intestinal Diseases

First Posted Date: 2019-09-25

Last Posted Date: 2021-07-27

Lead Sponsor: Takeda

Target Recruit Count: 19

Registration Number: NCT04102163

Locations: 🇪🇸
Hospital Universitario de Salamanca, Salamanca, Castilla Y Leon, Spain
🇪🇸
Hospital Gregorio Maranon, Madrid, Comunidad De Madrid, Spain
🇪🇸
Hospital Universitario Rio Hortega, Valladolid, Castilla Y Leon, Spain

and more 17 locations

A Study of TAK-994 in Adults With Type 1 and Type 2 Narcolepsy

Phase 2

Terminated

Conditions: Narcolepsy Type 1 (NT1)
Narcolepsy Type 2 (NT2)

Interventions: Drug: Placebo
Drug: TAK-994

First Posted Date: 2019-09-20

Last Posted Date: 2024-10-29

Lead Sponsor: Takeda

Target Recruit Count: 97

Registration Number: NCT04096560

Locations: 🇺🇸
Santa Monica Clinical Trials, Los Angeles, California, United States
🇺🇸
Florida Pulmonary Research Institute, LLC, Winter Park, Florida, United States
🇺🇸
SDS Clinical Trials, Inc., Santa Ana, California, United States

and more 75 locations

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-988 in Healthy Participants

Phase 1

Withdrawn

Conditions: Healthy Volunteers

Interventions: Drug: TAK-988
Drug: TAK-988 Placebo

First Posted Date: 2019-09-09

Last Posted Date: 2021-11-26

Lead Sponsor: Takeda

Registration Number: NCT04082481

Locations: 🇺🇸
PRA Health Sciences - Salt Lake City, Millcreek, Utah, United States
🇺🇸
Parexel Internalional - Glendale, Glendale, California, United States

Long-term Follow-up Study With Darvadstrocel in the Treatment of Complex Perianal Fistula

Phase 3

Completed

Conditions: Complex Perianal Fistula
Crohn's Disease

Interventions: Biological: Darvadstrocel

First Posted Date: 2019-09-03

Last Posted Date: 2024-05-06

Lead Sponsor: Takeda

Target Recruit Count: 151

Registration Number: NCT04075825

Locations: 🇪🇸
Hospital Clinico San Carlos, Madrid, Spain
🇺🇸
Virginia Mason Medical Center - Gastroenterology, Seattle, Washington, United States
🇺🇸
University of Miami Hospital, Miami, Florida, United States

and more 55 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy